Everything tagged "value" across research, earnings, and macro.
198 articles
U.S. Bancorp is pairing steady core banking growth with a strong fee engine and improving efficiency. The stock looks attractive for balanced investors as earnings expand and valuation remains reasonable.
Abbott is evolving from a defensive healthcare name into a stronger medtech-led compounder, helped by Medical Devices growth and the Exact Sciences deal. Nutrition remains a drag, but the stock looks attractive on weakness rather than at any price.
Biogen’s business has stabilized, with growth products and LEQEMBI helping offset legacy MS pressure. The stock still looks reasonably priced for a selective Buy as cash flow and mix improve.
Marsh & McLennan is executing well across broking and consulting, with 2025 revenue of $26.98B and Q1 2026 growth still running at 8%. The stock looks like a quality compounder, but valuation and leverage keep the upside measured.
Travelers combines elite underwriting, strong capital returns, and a fortress balance sheet, but the stock looks close to fully valued after a strong run. Buy on weakness, with upside constrained unless growth and pricing improve further.
Charles Schwab is turning record client growth, rising managed investing flows, and a stronger balance sheet into a steadier compounder. Valuation is reasonable, but rate sensitivity and cash behavior still matter.
BNY is executing well as a scaled financial infrastructure platform, with strong revenue growth, expanding margins, and raised 2026 guidance. Valuation is no longer cheap, so the stock looks best on pullbacks.
Cintas posted record fiscal 2026 revenue and margin expansion, but the stock still trades at a premium multiple. The report rates CTAS a Buy only on pullbacks, with fair value set at $205.
Progressive is pairing rapid policy growth with elite underwriting, making it one of the strongest operators in U.S. auto insurance. The stock still looks attractive, but valuation is no longer cheap after a big run.
BlackRock is using ETF dominance, Aladdin, and private-markets expansion to drive stronger revenue and earnings leverage. Q1 2026 showed powerful inflows, margin expansion, and rising mix quality.
Tower Semiconductor is a specialty foundry with strong Q1 2026 growth, record revenue guidance, and unusually visible silicon photonics demand. The stock looks attractive for growth investors, though valuation remains demanding.
Pentair is a balanced water-technology industrial with steady growth, expanding margins, and strong cash generation. The stock looks like a quality compounder, though valuation keeps the upside measured.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator